Psychiatry

BioVie Presents Data Supporting use of NE3107 in the Treatment of Alzheimer’s Disease at 2021 Alzheimer’s Association International Conference

Tuesday, July 27, 2021 - 1:00pm

BioVie has obtained authorization from the U.S. Food & Drug Administration to initiate a pivotal Phase 3 trial of NE3107 in Alzheimers Disease called the NM101 study ( NCT04669028 ).

Key Points: 
  • BioVie has obtained authorization from the U.S. Food & Drug Administration to initiate a pivotal Phase 3 trial of NE3107 in Alzheimers Disease called the NM101 study ( NCT04669028 ).
  • NM101 is a randomized double blind, placebo-controlled, US multicenter study of NE3107 in 316 subjects with mild to moderate Alzheimers Disease.
  • At the AAIC this year there are literally hundreds of presentations on inflammation and Alzheimers disease and dozens on insulin resistance and AD.
  • NE3107 is the first potentially disease modifying, anti-inflammatory insulin sensitizer therapy in a phase 3 trial, said Cuong Do, Chief Executive Officer of BioVie.

Lighthouse Autism Center and Cerberus Announce Strategic Partnership

Monday, July 26, 2021 - 1:00pm

Lighthouse Autism Center (Lighthouse or the Company) today announced a strategic investment by an affiliate of Cerberus Capital Management (Cerberus), a global leader in alternative investing.

Key Points: 
  • Lighthouse Autism Center (Lighthouse or the Company) today announced a strategic investment by an affiliate of Cerberus Capital Management (Cerberus), a global leader in alternative investing.
  • Lighthouse is a leading provider of center-based applied behavioral analysis (ABA) services for children diagnosed with autism spectrum disorder.
  • Nicholas Scola, Partner at Abry Partners, added: "We are excited to continue our partnership with the Lighthouse team and welcome the support of Cerberus.
  • Headquartered in South Bend, Indiana, Lighthouse is a leading provider of center-based autism behavioral health services for children diagnosed with autism spectrum disorder.

Alzheimer's Drug Discovery Foundation (ADDF) Investment Boosts Search for Digital Biomarkers for Early Alzheimer's

Monday, July 26, 2021 - 3:00pm

The Diagnostics Accelerator provides funding to fast-track the development of affordable and accessible diagnostic tools and biomarkers for Alzheimer's disease and related dementias.

Key Points: 
  • The Diagnostics Accelerator provides funding to fast-track the development of affordable and accessible diagnostic tools and biomarkers for Alzheimer's disease and related dementias.
  • Recent research shows that Alzheimer'salso causes subtle early changes in aspects of behaviour such as sleep, speech, interactions, and movement.
  • While undetectable to the human eye, these changes can now be picked up by commercially available digital technologies.
  • Founded in 1998 by Leonard A. and Ronald S. Lauder, the Alzheimer's Drug Discovery Foundation is dedicated to rapidly accelerating the discovery of drugs to prevent, treat and cure Alzheimer's disease.

Improving Air Quality Reduces Dementia Risk, Multiple Studies Suggest

Monday, July 26, 2021 - 3:00pm

While research has linked air quality and cognition previously, these new data at AAIC 2021 explore how air pollutants might impact dementia and what reducing them might mean for long-term brain health.

Key Points: 
  • While research has linked air quality and cognition previously, these new data at AAIC 2021 explore how air pollutants might impact dementia and what reducing them might mean for long-term brain health.
  • "But what's exciting is we're now seeing data showing that improving air quality may actually reduce the risk of dementia.
  • Air Quality Improvement May Slow Cognitive Decline and Reduce Dementia Risk in Older U.S. Women
    Although studies have found that improved air quality is associated with better respiratory health and longer life expectancy, it's unknown if improved air quality can also improve brain health.
  • Association of air quality reduction with incident dementia: effects of natural course and hypothetical air pollutant interventions using g-computation.

Break Free from Marijuana Addiction with New 30-Day Online Program

Monday, July 26, 2021 - 1:38pm

An innovative way to overcome marijuana addiction in the comfort of a customer's own home.

Key Points: 
  • An innovative way to overcome marijuana addiction in the comfort of a customer's own home.
  • The CAARE Program is a 30-day step-by-step program that has the tools needed to overcome marijuana addiction.
  • With the CAARE Program, users can follow a proven plan to break free of addiction, intentionally create the life they want, and live every day forward on their own terms.
  • To find out more about the CAARE Program or the highly-rated The Secret Addiction book, please visit www.secretaddiction.org .

Cyclerion Therapeutics to Present Clinical Trial Design for CY6463 Phase 2a Study in Participants with Alzheimer’s Disease with Vascular Pathology at the Alzheimer’s Association International Conference 2021 (AAIC)

Thursday, July 22, 2021 - 9:30pm

This pioneering work provides insights into the relationships between electrophysiological measures and cognitive performance in patients with Alzheimers disease and other dementias.

Key Points: 
  • This pioneering work provides insights into the relationships between electrophysiological measures and cognitive performance in patients with Alzheimers disease and other dementias.
  • Cyclerion identified changes in electrophysiological measures in the recent Phase 1 Translational Pharmacology study and will be evaluating electrophysiological and cognitive endpoints in the Phase 2a study in participants with Alzheimers disease with vascular pathology.
  • Title: Clinical trial design for a Phase 2a study evaluating the safety, tolerability, pharmacokinetics, and CNS activity of CY6463 in participants with Alzheimers disease with vascular pathology
    The poster presentation will be available beginning at 8 a.m. MT / 10 a.m.
  • The poster will also be available on the News & Events page of the Cyclerion website https://ir.cyclerion.com/news-events/event-calendar .

Accelerate360's Lifetogo Announces Partnership With The Mental Health Coalition, New Line Of Immunity-Boosting Gummies

Thursday, July 22, 2021 - 5:21pm

The partnership with The Mental Health Coalition kicks-off as the world approaches The World Health Organization's Self Care Day, Saturday, July 24.

Key Points: 
  • The partnership with The Mental Health Coalition kicks-off as the world approaches The World Health Organization's Self Care Day, Saturday, July 24.
  • LifeToGo will have a dedicated landing page with content, resources and information about The Mental Health Coalition, its members and programs.
  • For more information, visit accelerate360.com
    About The Mental Health Coalition:
    The Mental Health Coalition ( www.thementalhealthcoalition.org ) is a coalition of the Nation's leading mental health organizations, brands, and individuals who have joined forces to end the debilitating stigma surrounding mental health and to change the way people talk about, and care for, mental illness.
  • We will not relent until mental health is no longer associated with stigma, shame or judgement and all people feel empowered to openly discuss and address their individual mental health needs.

Caravel Autism Health Welcomes New Board Member

Thursday, July 22, 2021 - 3:30pm

CHICAGO, July 22, 2021 /PRNewswire/ -- Caravel Autism Health announced today the expansion of its board of directors with the addition of Michelle Wright.

Key Points: 
  • CHICAGO, July 22, 2021 /PRNewswire/ -- Caravel Autism Health announced today the expansion of its board of directors with the addition of Michelle Wright.
  • Caravel has focused on targeted industry experience as well as increasing board diversity and adding a parent's perspective.
  • "We are pleased to welcome Michelle as our board's newest member," said Mike Miller, Chief Executive Officer for Caravel.
  • Since 2009, Caravel Autism Health has been devoted to helping families navigate the challenges of childhood autism.

Alsana® Expands Eating Disorder Treatment in the Greater St. Louis Area with the Opening of its seventh Residential Treatment Center

Thursday, July 22, 2021 - 1:52pm

"Juneberry's clinical team is committed to delivering evidence-based, compassionate care that facilitates healing in all areas of our clients' lives.

Key Points: 
  • "Juneberry's clinical team is committed to delivering evidence-based, compassionate care that facilitates healing in all areas of our clients' lives.
  • "Alsana's treatment programs reflect our strong commitment to meeting clients where they are in their eating disorder recoveries," said Gayle Devin, CEO for Alsana.
  • Eating disorder treatment professionals are invited to take part in Alsana's Juneberry Opening Celebration on July 29.
  • Alsana is an eating recovery community that offers holistic, compassionate treatment that focuses on the total health and overall wellness of each individual client.

EDCare Kansas City Introduces New Adolescent Treatment Program

Thursday, July 22, 2021 - 1:03pm

KANSAS CITY, Mo., July 22, 2021 /PRNewswire/ -- EDCare is pleased to announce the opening of its second Adolescent Treatment Center.

Key Points: 
  • KANSAS CITY, Mo., July 22, 2021 /PRNewswire/ -- EDCare is pleased to announce the opening of its second Adolescent Treatment Center.
  • EDCare Kansas City was established in 2014 to expand EDCare's evidence-based eating disorder treatment program to the Midwest.
  • EDCare's Kansas City Adolescent Intensive Outpatient Program adds to the center's current treatment options for adults, including partial hospitalization, intensive outpatient and evening intensive outpatient treatment programs.
  • For more information about EDCare of Kansas City, or to schedule a free confidential assessment, please call 913-945-1277 or visit www.eatingdisorder.care/kansas-city-ks
    About EDCare: Since 2001, EDCare has been a leading provider of eating disorder treatment to patients across the United States and internationally.